<DOC>
	<DOCNO>NCT01337700</DOCNO>
	<brief_summary>Autism Spectrum Disorders ( ASD ) include Autistic disorder , Asperger 's syndrome Pervasive Developmental Disorder Not Otherwise Specified ( PDD-NOS ) . These developmental disorder begin prior three year age . Recent Centers Disease Control ( CDC ) estimate suggest ASD affect 1 100 individual 1 50 boy . There substantial cost associate care patient ASD , ASD high Caregiver Burden Scores condition . There three core symptom domains ASD , include social deficit , repetitive behavior language deficit . Patients also associate symptom attentional deficit , disruptive behavior intellectual disability . There currently Food Drug administration ( FDA ) approve treatment core symptom autism , risperidone aripiprazole FDA approval disruptive behavior associate autism . This 12 week randomize double blind placebo control trial Milnacipran adult ASD Aspergers Syndrome . Milnacipran say play role activation normalization locus coeruleus-noradrenergic system , hypothesize play role behavior adaptation performance .</brief_summary>
	<brief_title>Milnacipran Autism Functional Locus Coeruleus Noradrenergic Model Autism</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Asperger Syndrome</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Male Female patient Aged 1850 year Diagnosis Autism Spectrum Disorder IQ great 70 Pregnant subject Patients deem comprehensive psychiatric interview significant risk suicide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>ASD</keyword>
	<keyword>Autism</keyword>
	<keyword>Autism Spectrum Disorder</keyword>
	<keyword>Asperger Syndrome</keyword>
	<keyword>Asperger</keyword>
	<keyword>PDD</keyword>
	<keyword>PDD-NOS</keyword>
</DOC>